Centre caps trade margins on non-scheduled cancer drugs at 30%

The Centre has approved a 30% trade margin cap on non-scheduled cancer drugs to reduce treatment costs. Officials estimate the move could cut prices by up to 70% and save patients ₹2,500 crore annually. A government panel will identify eligible medicines, while the NPPA will issue the final notification. The cap will cover branded and generic drugs.